Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relmaclip α plus chemoradiotherapy in unresectable esophageal squamous cell carcinoma
ChiCTR2600130553Phase 2Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: 1-year progression-free survival rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ramucirumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600130553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130553.